Construction and evaluation of hepatitis C virus (HCV) DNA vaccine containing E2-gAD fusion gene.
- Author:
Bo WEN
1
;
Yao DENG
;
Wen-Jie TAN
;
Xiao YING
;
Ji-Ming GAO
;
Li RUAN
Author Information
- Publication Type:Journal Article
- MeSH: Adiponectin; administration & dosage; genetics; immunology; Animals; Female; Hepacivirus; genetics; immunology; Hepatitis C; immunology; prevention & control; Humans; Mice; Mice, Inbred BALB C; Recombinant Fusion Proteins; administration & dosage; genetics; immunology; Vaccines, DNA; administration & dosage; genetics; immunology; Viral Envelope Proteins; administration & dosage; genetics; immunology; Viral Hepatitis Vaccines; administration & dosage; genetics; immunology
- From: Chinese Journal of Experimental and Clinical Virology 2010;24(1):53-55
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo rational design HCV DNA vaccine candidates and evaluate their specific We design to construct two DNA vaccine candidates, one consists of immunity to HCV in mice.
METHODSWe design to construct two DNA vaccine candidates, one consists of E2 (the envelope glycoprotein 2 of HCV) gene only, the second consists of E2-gAD (Globular Domain of Human Adiponectin) fusion gene via overlapping PCR. Confirm the expression of the DNA vaccines by Western blotting, and then vaccinated by injection of DNA vaccines with gene electrotransfer (GET) in BALB/c mice. The immune response was measured by IFN-gamma ELISPOT.
RESULTSThe DNA vaccine candidate consists of E2-gAD could effectively express in vitro , and it could induced a higher anti-HCV T cell response in mice than the one consists of E2 only.
CONCLUSIONThe HCV DNA vaccine consists of E2-gAD fusion can increase the immunity of the E, to some extend, and the research paved a way to develop and optimize the novel HCV DNA vaccine.
